MarketFriction

Vineet Laboratories Ltd

NSE VINEETLAB · BSE 543298 · Pharmaceuticals
₹35.91 -3.36%
NSE close2026-10-01
52 week range27.96 - 43.50
Market cap₹70.4 Cr.
P/E63.4
Price band 5% Delivery 73.4%

Price

Drag to pan, scroll or pinch to zoom. Ruler (or Shift + drag) measures a move.Dashed lines: 52 week high and low. Prices adjusted for splits and bonuses.

Financials

Standalone, Rs crore
Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Sales37.5243.3732.6537.0523.8618.9618.1014.087.4417.4215.6518.89
Expenses37.2639.2033.2933.6324.6519.2722.2325.127.1314.2413.1716.40
Operating Profit0.264.17-0.643.42-0.79-0.31-4.13-11.040.313.182.482.49
OPM %0.69%9.61%-1.96%9.23%-3.31%-1.64%-22.82%-78.41%4.17%18.25%15.85%13.18%
Other Income0.030.010.010.410.370.200.031.380.020.010.050.03
Interest0.961.021.081.721.140.990.950.900.612.191.090.99
Depreciation0.610.610.630.670.610.620.620.660.630.630.630.54
Profit before tax-1.282.55-2.341.44-2.17-1.72-5.67-11.22-0.910.370.810.99
Tax %-2.34%4.71%-11.11%-34.03%-1.84%6.98%0.53%-6.24%-4.40%-8.11%-3.70%27.27%
Net Profit-1.252.42-2.071.92-2.13-1.83-5.71-10.53-0.870.400.850.73
EPS in Rs-0.651.26-1.081.00-1.11-0.95-2.97-5.48-0.450.210.440.38
Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Sales-0.00243.48191.10212.29150.5975.0059.40
Expenses0.01235.33177.94204.63143.3991.2850.91
Operating Profit-0.018.1513.167.667.20-16.288.49
OPM %3.35%6.89%3.61%4.78%-21.71%14.29%
Other Income-0.000.390.290.120.461.990.10
Interest-0.002.672.093.384.783.984.89
Depreciation-0.001.812.022.372.522.502.41
Profit before tax-0.014.069.342.030.36-20.771.29
Tax %-0.00%56.16%28.91%38.42%-183.33%-2.79%13.18%
Net Profit-0.011.786.641.251.03-20.191.11
EPS in Rs-0.110.933.460.650.54-10.520.58
Dividend Payout %-0.00%-0.00%13.89%-0.00%-0.00%-0.00%-0.00%
10 Years5 Years3 YearsTTM1 YearLast Year
Compounded Sales Growth%-25%-35%-21%
Compounded Profit Growth%-9%-4%105%
Stock Price CAGR%-11%-6%11%
Return on Equity%-8%-23%4%
Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital0.419.229.229.229.229.2219.21
Reserves-0.0117.4024.0024.4625.515.4326.40
Borrowings-0.0012.4826.5131.0944.3040.0545.33
Other Liabilities-0.0069.6473.5951.0837.8439.8433.84
Total Liabilities0.40108.74133.32115.85116.8794.54124.78
Fixed Assets-0.0019.6721.3826.6526.9225.4624.24
CWIP-0.00-0.00-0.00-0.00-0.00-0.00-0.00
Investments-0.000.120.140.130.180.210.19
Other Assets0.4088.95111.8089.0789.7768.87100.35
Total Assets0.40108.74133.32115.85116.8794.54124.78
Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity-0.0027.497.63-9.62-6.6111.49-12.03
Cash from Investing Activity-0.00-7.81-3.68-6.69-2.22-3.18-1.11
Cash from Financing Activity-0.0018.6211.960.278.43-8.2329.74
Net Cash Flow-0.0038.3015.91-16.03-0.400.0816.60
Free Cash Flow-0.0027.497.63-17.25-9.4010.44-13.23
CFO/OP-0%327%82%-87%-88%-71%-144%
Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days64.0369.1460.4576.5964.4870.05
Inventory Days73.12109.1997.79158.26259.67606.03
Days Payable114.08161.2073.90103.37174.65239.52
Cash Conversion Cycle23.0717.1384.34131.48149.50436.56
Working Capital Days14.41-19.4620.6328.48-37.2888.98
ROCE %34.08%23.13%8.69%6.65%-27.95%8.49%
Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters38.66%37.55%37.50%37.50%36.07%35.85%35.85%29.26%15.89%12.46%5.98%5.98%
FIIs0.00%0.24%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.36%0.50%
Public61.34%62.20%62.50%62.49%63.93%64.15%64.15%70.74%84.11%87.54%93.67%93.52%
No. of Shareholders9,4699,5149,6389,52310,30010,05810,0259,9889,68210,0039,9299,901

Fundamentals

Market Cap₹ 70.4 Cr.
Current Price₹ 36.6
Stock P/E63.4
Book Value₹ 23.8
ROCE8.49 %
ROE3.68 %
Dividend Yield0.00 %
Face Value₹ 10.0
Compounded Sales Growth (TTM)-21%
Compounded Profit Growth (TTM)105%
Standalone figures.
Valuation
Market capRs 69 Cr
Enterprise valueRs 99 Cr
P/E (TTM)62.14x
Price to book2.05x
Price to sales1.16x
EV / EBITDA11.57x
EV / EBIT16.14x
EV / sales1.67x
Earnings yield1.61%
P/E, 3-year average15.68x
P/B, 3-year average1.04x
Profitability
Operating margin (excl. other income)3.61%
Operating margin (incl. other income)3.66%
EBITDA margin14.43%
Pre-tax margin2.12%
Net profit margin1.87%
Net margin, latest quarter3.86%
ROE3.74%
ROCE8.69%
ROA1.00%
ROE, 3-year average13.04%
ROCE, 3-year average21.97%
ROA, 3-year average3.25%
ROIC (approx.)5.92%
Tax rate38.42%
Other income / net worth0.36%
Growth
Sales growth (latest year)11.09%
Profit growth (latest year)-81.17%
Sales growth QoQ20.70%
Profit growth QoQ-14.12%
Sales growth YoY (latest quarter)34.16%
Per share
EPS (TTM)Rs 0.58
EPS (latest year)Rs 1.36
EPS (latest quarter)Rs 0.38
EPS, 3-year averageRs 3.50
Book value per shareRs 17.53
Sales per shareRs 30.92
Cash flow per shareRs -5.01
Free cash flow per shareRs -6.89
Dividend per share, 3-year averageRs 1.00
Dividends
Dividend payout, 3-year average13.86%
Efficiency
Asset turnover1.83x
Fixed asset turnover7.97x
Inventory turnover4.16x
Inventory days88 days
Debtor days60 days
Debtors turnover6.04x
Creditor days240 days
Cash conversion cycle437 days
Working capital days89 days
Leverage
Total debtRs 31 Cr
Cash and bankRs 1 Cr
Net debtRs 30 Cr
Debt to equity0.92x
Net debt / EBITDA3.52x
Interest coverage1.26x
Owners' fund to total sources29.07%
Debt to assets26.84%
Cash flow
Cash from Operating Activity (latest year)Rs -10 Cr
Cash from Investing Activity (latest year)Rs -7 Cr
Cash from Financing Activity (latest year)Rs 0 Cr
Net Cash Flow (latest year)Rs -16 Cr
Free cash flow (latest year)Rs -13 Cr
FCFE (approx.: FCF + change in debt)Rs -9 Cr
Statement figures
Net sales (TTM)Rs 59 Cr
Net sales (latest year)Rs 212 Cr
Sales (latest quarter)Rs 19 Cr
Operating profit excl. other income (latest year)Rs 8 Cr
Operating profit (latest quarter)Rs 2 Cr
Other income (TTM)Rs 0 Cr
EBITDA (TTM)Rs 9 Cr
PBDT (TTM)Rs 4 Cr
Profit before tax (TTM)Rs 1 Cr
Tax (latest year)Rs 1 Cr
Net profit (TTM)Rs 1 Cr
Net profit (latest year)Rs 1 Cr
Net profit (latest quarter)Rs 1 Cr
Depreciation (TTM)Rs 2 Cr
Depreciation (latest quarter)Rs 1 Cr
Interest (TTM)Rs 5 Cr
Cost of goods sold (latest year)Rs 192 Cr
Total expenditure (latest year)Rs 205 Cr
Total income (latest year)Rs 212 Cr
Share capitalRs 9 Cr
ReservesRs 24 Cr
Shareholders' fundsRs 34 Cr
Total assetsRs 116 Cr
Net blockRs 27 Cr
InvestmentsRs 0 Cr
ReceivablesRs 35 Cr
InventoryRs 46 Cr
Other liabilitiesRs 51 Cr
Shares outstanding (crore)1.92
Ownership
Promoter holding5.98% (-23.28 in a year)
Computed by MarketFriction from the standalone statements. Returns use average balances.
P/B 2.05 is at the 28th percentile (median 2.26).
Monthly. Market cap from split-adjusted price; profit and book value as reported by that month. A low percentile means cheap versus its own history, not cheap versus peers.
PeriodVINEETLABNifty 50Difference
1 week+2.8%-2.8% +5.6 pts
1 month-5.4%-6.8% +1.4 pts
3 months+6.7%-7.6% +14.3 pts
6 months+23.6%+0.4% +23.2 pts
1 year+1.3%-9.9% +11.2 pts
2 years-38.8%-13.6% -25.3 pts
3 years-29.0%+14.2% -43.2 pts
5 years-53.3%+27.9% -81.2 pts

Red flags

F-score 3 of 8
explainShare dilution Share count up 0% in a year, 2033% in three
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.

Latest quarter

Mar 2026
Sales ₹19 Cr +34.2% vs Mar 2025. Net profit ₹1 Cr +106.9%.
Against our estimate for Mar 2026: sales +50.5%, profit +223.7% in line. Our estimate for Jun 2026: sales Rs 8 Cr, profit Rs 0 Cr (how).

Activity

Compare
CompanyMcap (Cr)P/EROCE
Sun Pharmaceutical Industries Ltd447,47635.420.5 %
Divis Laboratories Ltd250,36384.022.0 %
Torrent Pharmaceuticals Ltd186,15283.415.2 %
Zydus Lifesciences Ltd119,75024.621.1 %
Cipla Ltd111,43031.115.5 %
Laurus Labs Ltd106,92897.817.8 %
Mankind Pharma Ltd105,12049.313.5 %
Dr Reddys Laboratories Ltd104,49432.413.0 %
Aurobindo Pharma Ltd97,68225.812.9 %
Lupin Ltd93,84015.829.9 %
Glenmark Pharmaceuticals Ltd68,90522.139.8 %
Alkem Laboratories Ltd62,77227.621.2 %
Biocon Ltd61,43984.53.61 %
Abbott India Ltd57,94935.944.8 %
Gland Pharma Ltd49,33343.115.1 %
DateClientSideQtyPrice
2026-09-29Mangal Keshav Capital LimitedBUY800,00036.77
2026-09-29Mallukuntla LakshmideviSELL180,00036.84
2026-09-29Iswarya GajjalaSELL291,00036.73
Ex-dateActionFactor
2025-12-23Rights 13:12 @ Premium Rs 20/-
2024-09-17Annual General Meeting
2023-09-18Annual General Meeting
2022-09-19Dividend - Re 1 Per Share
2021-09-22 Annual General Meeting
DateTypeWhat it says
2026-09-30ResignationResignation of NSVR & Associates LLP as of the company w.e.f. September 29, 2026.
2026-09-19General UpdatesGeneral UpdatesSub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Grant of extensio...
2026-09-08Clarification - Financial ReThe Exchange has sought clarification from Vineet Laboratories Limited for the quarter ended 30-Jun-2026 with respect to Regulation 33 of the SEBI (Li...
2026-08-29General UpdatesGeneral Updates
2026-08-25Board meeting outcomeVineet Laboratories Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
2026-08-25Board meeting outcomeVineet Laboratories Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.The Board of Directors of the compa...
2026-08-14Monitoring Agency ReportPlease find the attached Monitoring Agency Report issued by CRISIL rating Limited for quarter ended June 30, 2026
2026-07-30Quarterly Compliance Report Vineet Laboratories Limited has informed regarding Submission of the Compliance Report on Corporate Governance for the Q_ FY 20__-__
2026-07-21CessationCessation of Mr. Gaddam Venkata Ramana (DIN: 00031873) as Managing Director of the company w.e.f. July 21, 2026.
2026-07-21Director changeChange in Director(s) of the company.
2026-07-16General UpdatesIntimation regarding deferment of Board Meeting.
2026-07-11General UpdatesGeneral Updates
2026-06-24Disclosure under SEBI TakeovA SRINIVASA RAJU has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial ...
2026-05-30General UpdatesGeneral UpdatesOutcome of Board Meeting Held on May 30, 2026 Deferment of Consideration of Audited Standalone Financial Results
2026-05-30ResignationResignation of Director/KMP/SMP
2026-05-29ResignationResignation of as Company Secretary & Compliance Officer of the company w.e.f. May 29, 2026.
2026-05-15Monitoring Agency ReportPlease find attached the Monitoring Agency Report issued by Crisil Ratings Limited for the quarter ended March 31 2026.
2026-04-29Quarterly Compliance Report Vineet Laboratories Limited has informed regarding Submission of the Compliance Report on Corporate Governance for the Quarter ended 31 march FY 2026
2026-04-21Structural Digital DatabaseSDD Compliance Certificate
2026-02-14Board meeting outcomeOutcome of Board Meeting held on Saturday, February 14, 2026 as required underRegulation 30 of Securities and Exchange Board of India (Listing Obligat...
2026-02-14Board meeting outcomeThe Board of Directors of the company in its meeting held today i.e., Saturday, February 14, 2026 has:1. considered and approved the unaudited standal...
2026-02-07Shareholder meetingWe are hereby submitting the voting results of the Extra-Ordinary General Meeting of Vineet Laboratories Limited held on Saturday, February 07, 2026.
2026-02-07Shareholder meetingProceedings of Extraordinary General Meeting held on February 07, 2026 along with a copy of minutes.
2026-02-04General UpdatesWe are hereby submitting the trading approvals received from BSE and NSE vide their letters dated February 04, 2026 for the Equity shares allotted und...
2026-02-02Committee Meeting UpdatesWe would like to inform that the Rights Issue Committee of the Board of Directors of Vineet Laboratories Limited ( the Company ) has today i.e. Februa...
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
Less than 100 unique PAN traded in previous 30 days

Quick answers

What is the market cap of Vineet Laboratories Ltd?

Vineet Laboratories Ltd (VINEETLAB) has a market capitalisation of Rs 70.4 Cr. at the 2026-10-01 close.

What is the P/E ratio of Vineet Laboratories Ltd?

Vineet Laboratories Ltd trades at a P/E of 63.4 on trailing twelve-month profit, at the 2026-10-01 close.

What were Vineet Laboratories Ltd's latest quarterly results?

In the Mar 2026 quarter, Vineet Laboratories Ltd sales was Rs 19 Cr (+34.2% vs Mar 2025) and net profit was Rs 1 Cr.

What is the 52-week high and low of Vineet Laboratories Ltd?

The 52-week high is Rs 43.50 and the 52-week low is Rs 27.96.

Data: NSE and BSE daily reports, company filings. Numbers only, not investment advice, not a SEBI-registered research service.AboutMethodologyFAQResearchContactTermsPrivacyDisclaimerUpdated 2026-10-03